Legendary market commentator Jim Cramer recently heaped praise on asset manager BlackRock, Inc. (NYSE: BLK), lauding the company for an impressive quarter and recommending it as a “buy.”
The Securities and Exchange Commission (SEC) has extended the deadline for a decision on the proposed Ethereum exchange-traded fund by BlackRock to March 10, delaying the assessment of its potential impact.
Addressing Axsome Therapeutics, Inc. (NASDAQ: AXSM), Cramer expressed caution, emphasizing his need for further research due to historical challenges faced by several companies operating in the central nervous system field.
RBC Capital initiated coverage on Axsome Therapeutics, highlighting the undervalued near-term revenue growth and pipeline opportunities. The firm assigned Axsome an “Outperform” rating with a price target of $126.
Axsome Therapeutics recently announced a preliminary fourth-quarter 2023 product revenue of approximately $71 million, contributing to a total revenue of $204 million for the full year of 2023.
Discussing SolarEdge Technologies, Inc. (NASDAQ: SEDG), Cramer described it, along with Enphase Energy, Inc. (NASDAQ: ENPH), as “too hard to own.”
SolarEdge Technologies recently disclosed a reduction of 16% of its workforce aimed at streamlining operating expenses and aligning its cost structure with evolving market conditions. This decision is expected to impact around 900 employees, with 500 of them working at the company’s manufacturing sites.
Goldman Sachs analyst Brian Lee maintained a “Sell” rating on SolarEdge Technologies and revised the price target down from $83 to $71.
Price Action: SolarEdge gained 0.3% to close at $70.44, while Enphase shares dropped 1.2% to $106.83 on Thursday. BlackRock shares rose 0.6% to $790.46, while Axsome Therapeutics declined 1.3% to $90.59 during Thursday’s session.